DIA1R Is an X-Linked Gene Related to Deleted In Autism-1 by Aziz, Azhari et al.
DIA1R Is an X-Linked Gene Related to Deleted In
Autism-1
Azhari Aziz, Sean P. Harrop
¤, Naomi E. Bishop*
Department of Microbiology, La Trobe University, Bundoora, Victoria, Australia
Abstract
Background: Autism spectrum disorders (ASDs) are frequently occurring disorders diagnosed by deficits in three core
functional areas: social skills, communication, and behaviours and/or interests. Mental retardation frequently accompanies
the most severe forms of ASDs, while overall ASDs are more commonly diagnosed in males. Most ASDs have a genetic origin
and one gene recently implicated in the etiology of autism is the Deleted-In-Autism-1 (DIA1) gene.
Methodology/Principal Findings: Using a bioinformatics-based approach, we have identified a human gene closely related
to DIA1, we term DIA1R (DIA1-Related). While DIA1 is autosomal (chromosome 3, position 3q24), DIA1R localizes to the X
chromosome at position Xp11.3 and is known to escape X-inactivation. The gene products are of similar size, with DIA1
encoding 430, and DIA1R 433, residues. At the amino acid level, DIA1 and DIA1R are 62% similar overall (28% identical), and
both encode signal peptides for targeting to the secretory pathway. Both genes are ubiquitously expressed, including in
fetal and adult brain tissue.
Conclusions/Significance: Examination of published literature revealed point mutations in DIA1R are associated with X-
linked mental retardation (XLMR) and DIA1R deletion is associated with syndromes with ASD-like traits and/or XLMR.
Together, these results support a model where the DIA1 and DIA1R gene products regulate molecular traffic through the
cellular secretory pathway or affect the function of secreted factors, and functional deficits cause disorders with ASD-like
symptoms and/or mental retardation.
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Introduction
Autism spectrum disorders (ASDs) encompass a variety of
syndromes, diagnosed on the basis of three core symptoms: deficits
in social skills, impaired use of language, and restricted and stereotypic
behaviours and/or interests [1]. Classical ‘autistic disorder’ (AD) falls
under the ASD umbrella and, in addition to the three core symptoms,
is frequently accompanied by mental retardation, as indicated by an
intelligence quotient (IQ) of ,70 [2–11]. By contrast, presence of the
core ASD symptoms accompanied by an average (or above) IQ, is
typically classified as Asperger syndrome or high-functioning autism
[6,12,13]. The term pervasive development disorder (PDD) is often
used as a broader diagnostic descriptor, to encompass not only all
ASDs, but also PDD-not-otherwise-s p e c i f i e d( P D D - N O So ra t y p i c a l
autism), Rett disorder and childhood disintegrative disorder [14].
ASDs cause morbidity in as many as 1:60 people, with the incidence
being as high as 1:40 in males [15–19].
ASDs have an almost exclusive genetic origin [20–25]. The
concordance rate for monozygotic twins, from various studies,
ranges from 36% to as high as 100% in one study on female twins,
while concordance rates of dizygotic twins are reported to vary
from 0% to 31%, with values as high as 40% for male-male twin
pairs, and heritability estimates of ,90% have been calculated
[21,25–35]. In twin studies, when a broader definition of ASD is
used, higher concordance rates are found; while lower rates are
determined when a stricter definition of autistic disorder is used.
These findings indicate that the severity of ASD symptoms (e.g.
AD versus AS/HFA or PDD-NOS) and the age of diagnosis can
differ between monozygotic twins diagnosed with ASD [26,28–
30,34]. As a result, epigenetic influences have been suggested to
contribute to the overall ASD phenotype [36–39]. Recent data
also indicate a further ,10% of ASD cases are caused by
spontaneous genetic mutations [40–43]. Currently, more than 25
different loci encode ASD-susceptibility genes, with many more
being investigated [44]. Some, but not all, of the genes implicated
in ASD overlap with those implicated in MR [45–48].
Nonetheless, no genetic susceptibility locus accounts for more
than a small percentage of ASD cases [49]. While these findings
demonstrate an etiological heterogeneity for ASDs, many of the
genes appear to interact at the level of molecular pathways,
making it likely that mutations of one ASD-implicated gene may
affect the function of others [50]. These findings suggest a
common pathway(s) for the etiology of ASDs and raise hope that
common treatments may be developed.
It is rare for those with ASDs to lead independent lives in
adulthood, and those with severe intellectual disability (IQ,50)
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improved for those with an ASD who lack accompanying mental
retardation (MR), and 10–15% of those with Asperger syndrome/
high-functioning ASD achieve independence in adulthood [55–
57]. While these studies highlight the debilitating life-long effects of
ASDs, they emphasize the additional problems conferred by the
presence of intellectual disability. As with ASDs, X-linked mental
retardation (XLMR) is more common in males and also has a
heterogenous genetic etiology [58]. MR affects around 2% of the
population and accounts for 5–10% of the health care budget in
developed countries [58], with XLMR representing between 5–
15% of all MR [59]. Mutations in approximately 10% of the 2,000
genes on the human X chromosome can cause XLMR, although
the cellular role of most of these genes remains uncharacterized
[60].
We report the identification of a human gene related to the
recently identified Deleted In Autism 1 (DIA1) gene. The DIA1 gene
was identified in a genetic study for ASD genes [61], where it was
found that hemizygous DIA1 deletions were asymptomatic, while a
homozygous DIA1 deletion coincided with a classical autism
diagnosis. Using a bioinformatics-based approach, we have
identified a DIA1-related gene, we term DIA1R, which localizes
to the human X chromosome at position Xp11.3. Deletion and/or
mutation of human DIA1R is associated with ASD-like syndromes
and/or XLMR.
Results
Identification of a human DIA1-related gene
The human c3orf58 gene, found at chromosome position 3q24,
has recently been renamed DIA1 on the basis of its deletion in
ASD [61]. Human DIA1 has a known orthologue in both the
mouse (Mus musculus) and rat (Rattus norvegicus) genomes, where it is
alternatively called 1190002N15Rik, Ab2-095 or GoPro49 [62]. A
search of the HomoloGene database [63], revealed further DIA1
orthologues in the chimpanzee (Pan troglodytes), dog (Canis familiaris),
cow (Bos taurus), mouse (Mus musculus), chicken (Gallus gallus), and
zebrafish (Danio rerio) genomes (data not shown; [64]). Unexpect-
edly, a Basic Local Alignment Search Tool (BLAST) search [65] of
the non-redundant (NCBI) database [63,66], using the sequence of
the human DIA1 gene product, revealed a significantly similar
human gene product, LOC79742. This gene product was encoded
by the cXorf36 gene (for accession numbers and identifiers, see
Table 1) and localized to the human X chromosome at position
Xp11.3 (Figure 1). We have renamed this gene DIA1R (DIA1-
Related). A search of the HomoloGene database [63] revealed
orthologues of DIA1R in the cow, mouse, chicken, and zebrafish
genomes (data not shown).
Comparison of the human DIA1 and DIA1R gene
products
The human DIA1 and DIA1R genes encode gene products of
430 and 433 residues, respectively, with predicted molecular
weights of 49.5 and 48.6 kDa. To compare the human DIA1 and
DIA1R proteins with each other, we used two methods: BLAST
analyses and amino acid alignments. Pair-wise protein BLAST
analyses generate ‘expect values’ (E-values), where values less than
one are considered significantly similar, and the smaller the E-
value, the greater the similarity [65]. E-values of 2e-42 and 1e-42
were obtained for reciprocal BLAST searches, comparing the
human DIA1 gene product with that of DIA1R, or vice versa. Next,
amino acid alignments were employed to compare the human
DIA1 and DIA1R proteins at the amino acid level (Figure 2).
Amino acid alignments revealed human DIA1 and DIA1R are
62% similar overall (28% identical, and 34% similar, residues),
with similarity greater in the central portion of the two proteins,
Table 1. Accession numbers and identifiers for human DIA1 and DIA1R.
Database DIA1 identifier or accession number DIA1R identifier or accession number
HUGO gene symbol* c3orf58 cXorf58
RefSeq** protein NP_775823 NP_789789
RefSeq mRNA NM_173552 NM_176819
RefSeq chromosome NC_000003 NC_000023
GenInfo (GI) 27734895 193804854
ENSEMBL protein ENSP00000320081 ENSP00000381086
ENSEMBL transcript ENST00000315691 ENST00000398000
ENSEMBL gene ENSG00000181744 ENSG00000147113
UniProt Q8NDZ4 Q9H7Y0
UniGene Hs.288954 Hs.98321
Entrez gene GeneID 205428 79742
HGNC*** 28490 25866
Aliases LOC205428
MGC33365
GoPro49
Ab2-095
DIA1
LOC79742
DKFZp313K0825
EPQL1862
FLJ55198
FLJ14103
PRO3743
bA435K1.1
FLJ55198
*Human genome organization (HUGO) official gene name.
**NCBI non-redundant reference sequence [63].
***HUGO gene nomenclature committee (HGNC) identifier.
doi:10.1371/journal.pone.0014534.t001
A DIA1-Related Gene
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similarity suggests that the central region of DIA1 and DIA1R
encodes a biological function common to the two gene products.
Signal peptides in human DIA1 and DIA1R
Most proteins transported to the endoplasmic reticulum (ER)
have a stretch of hydrophobic amino acids at their amino-
terminus, known as the signal peptide (SP), which are recognized
by the signal recognition particle (SRP) to facilitate ER import
[67]. The length of signal peptides usually falls within a range of 5–
60 residues. Subsequent to SRP recognition, SPs are typically
cleaved from the imported pre-protein by signal peptide peptidase
activity [68]. Most imported proteins are then transported from
the ER to the Golgi apparatus [69]. As determined above, the
most disparate region found when DIA1 and DIA1R are aligned
(Figure 2) is the extreme amino-terminus. In a previous assessment
of the rat DIA1 gene product, the presence of a predicted signal
peptide was detected, and functionally supported by localization of
DIA1 to the lumen of the Golgi apparatus [62]. We therefore
analyzed the human DIA1 and DIA1R gene products for the
presence of amino-terminal signal peptides.
There are a variety of algorithms designed to predict the
presence of signal peptides, and we used three of the best-
performing algorithms [70,71] to both analyze the DIA1 and
DIA1R gene products for signal peptides, and to predict the signal
peptide cleavage sites. The methodologies used were: (i) the neural
network (NN) algorithm of SignalP v3.0 [72], (ii) the hidden
Markov model (HMM) of SignalP v3.0 [72], and (iii) the SigCleave
algorithm [73] at EMBOSS [74]. No trans-membrane domains
were predicted, nor ER-retrieval or retention motifs, in either
DIA1 or DIA1R (data not shown).
Our analyses revealed SPs in human DIA1 and DIA1R, using
all three prediction methods (Figures 3 and S1; data not shown).
However, while all methods predicted a SP in both DIA1 and
DIA1R, some methods used had varying success in pin-pointing
the exact cleavage site used to generate the mature protein. The
HMM algorithm of SignalP confidently (score of 0.544, where 0.5
is considered significant) predicted the signal peptide cleavage site
of human DIA1 (Figure 3A) as between amino acids 37 and 38
(SLLA-SWQR using single-letter amino-acid code, where the
hyphen indicates the site of cleavage). The same site was also the
highest-scoring cleavage site predicted by SigCleave (score 7.79,
where a score over 3.50 is considered significant), providing
confidence that this is the site of human DIA1 SP cleavage. By
contrast, the NN algorithm did not predict a DIA1 cleavage site
with a significant score (Figure S1A). For human DIA1R, two
cleavage sites were suggested by the HMM algorithm (Figure 3B),
but neither score passed into the significant range (0.26 for
cleavage between amino acids 31 and 32, 0.35 for between amino
acids 38 and 39, where 0.5 is considered significant). The NN
algorithm (Figure S1B) only predicted a single DIA1R cleavage
site (between amino acids 31 and 32) with a Y-score close to
significance (a Y-score of 0.44, where a Y-max value of 0.5 is
considered significant). SigCleave analysis of DIA1R (data not
shown) provided a highly significant score for cleavage between
amino acids 31 and 32 (CSFS-LPAS, using single-letter amino-
acid code, where the hyphen indicates the site of cleavage) of 10.23
(where values of greater than 3.5 are considered significant),
suggesting this may represent the true site of SP cleavage for
human DIA1R. Therefore, while all methods indicate amino-
terminal SPs in both DIA1 and DIA1R, the exact SP cleavage sites
will need to be determined experimentally. Together, our data
indicate that both the DIA1R and DIA1 gene products will be
translocated into the ER, and transported to the Golgi apparatus.
Ubiquitous tissue expression of human DIA1 and DIA1R
To determine the cell types and tissues in which human DIA1
and DIA1R are expressed, we explored the relevant expressed
sequence tag (EST) profiles via UniGene [63] and searched two
microarray databases: the GeneNote normal human expression
database at the Weizmann Institute [75] and human Gene Atlas
[76] at BioGPS [77].
EST profile data detected DIA1 expression at levels of 61
transcripts per million (TPM) isolated from brain tissue (Table 2)
and DIA1R at 25 TPM from brain tissue (Table 3). Of note, a wide
analysis of human gene expression levels, in 14 different tissues,
selected cut-off values for gene expression, with ‘low’ being #37
TPM and ‘high’ being $134 TPM [78]. Another human
expression study indicated the majority (64%) of genes are
expressed at between 3–50 TPM, 6% at levels between 100–
5,000 TPM, and only 0.03% expressed at levels above 10,000
TPM [79]. Using these values as a guide, DIA1R can be described
as being expressed at low-to-intermediate levels. By contrast, while
DIA1 is frequently expressed at low-to-intermediate levels,
expression is high in mammary gland (135 TPM), ‘mouth’ (223
TPM; where libraries included in this tissue category are often
derived from head or tongue), and vascular tissue (135 TPM). Ear
expression of DIA1 was the highest of those tissues falling in the
intermediate range, and is close (123 TPM) to the ‘high expression’
category. These four tissue types, apparently expressing high levels
of human DIA1, are all tissues with a high secretory output. One
explanation is that Golgi apparatus-localized DIA1 has a role in an
aspect of secretion common to these tissues. Abnormalities in
secreted levels of vascular growth factors and soluble vascular
receptors have been reported in patients with ASD [80], as have
abnormal levels of the endothelial cell protein PECAM-1 (platelet
endothelial cell adhesion molecule-1) [81]. Defects in secretion or
Figure 1. Chromosomal ideogram representation of the
location of human DIA1 (c3orf58) and DIA1R (cXorf36). (A) DIA1
localization on human chromosome 3 at position 3q24. (B) DIA1R
localization on the human X chromosome at position Xp11.3. Gene
localization is indicated by a modified red arrowhead on the right-hand
side, and a light-grey line extending through the text on the left-hand
side.
doi:10.1371/journal.pone.0014534.g001
A DIA1-Related Gene
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media [82], a condition occurring 2 to 3 times more frequently in
those with ASD, than those without ASD [83–85]. Therefore,
EST profiling results indicate widespread expression of human
DIA1 and DIA1R at moderate levels, including in brain tissue, with
higher levels of DIA1 in some tissues with a high secretory load.
Microarray data from two sources (Figures 4, S2, and S3)
supported the findings of the EST profiling results, as ubiquitous
expression of both DIA1 and DIA1R was found, including
expression in brain tissue. Microarray expression levels of human
DIA1 were strikingly similar in all tissue types tested, but no
confirmation of higher levels in ‘mouth’ tissues (tonsil, trachea,
salivary gland, and tongue, being the comparable microarray
tissue data), vascular tissue (CD105+ circulating endothelial cells
being the closest microarray data), or mammary gland (no
comparable microarray data) detected by EST profiling was
Figure 2. Amino acid sequence comparison of human DIA1 and human DIA1R. The sequence alignment was generated using CLUSTALX
[164]. Identical amino acids are highlighted in red font and indicated below the alignment with an asterisk (*). Strongly similar amino acids are
highlighted in green font and indicated below the alignment with a colon (:). Weakly similar amino acids are highlighted in blue font and indicated
below the alignment with a full stop (.). Dissimilar amino acids are in black font. Amino acid numbering is provided above the alignment. Human
DIA1 is 430, and DIA1R 433, amino acids in their immature forms (before signal peptide cleavage). Gaps required for optimal alignment are indicated
by dashes. The two proteins have 28% identical, 21% strongly similar, and 13% weakly similar, residues. Standard single-letter amino acid
abbreviations are used.
doi:10.1371/journal.pone.0014534.g002
A DIA1-Related Gene
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level of DIA1 was found in BDCA-4 (blood dendritic cell antigen 4
or neuropilin-1 or CD304) -positive plasmacytoid dendritic cells
(Figure S2), which secrete high levels of type I interferons [86]. By
contrast to the DIA1 microarray data, microarray expression levels
of DIA1R were less uniform (Figures 4 and S3). However, the
highest DIA1R expression level found in the Gene Atlas
microarray, which was found in liver (Figure S3), was not
Figure 3. Prediction of signal peptides in human DIA1 and DIA1R. The amino acid sequence of (A) human DIA1 or (B) human DIA1R, was
evaluated for amino-terminal signal peptides using the hidden Markov model of SignalP v3.0 [72]. C-region (cleavage-recognition region) scores are
in aqua, H-region (hydrophobic region) scores are in dark blue, N-region (N-terminal signal peptide sequence) scores are in green, and the cleavage
probability (that a given amino acid is the first in the mature protein) indicated in red. The significance cut-off value for all probability scores is 0.5,
and is indicated by a blue dotted line. Standard single-letter amino acid abbreviations and numbering is provided below the graph.
doi:10.1371/journal.pone.0014534.g003
A DIA1-Related Gene
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DIA1 gene expression in human tissues.
cDNA library source* TPM** EST/total***
adipose tissue 0 0/13105
adrenal gland 0 0/33195
ascites 0 0/40013
bladder 0 0/29757
blood 0 0/123476
bone 13 1/71655
bone marrow 81 4/48798
brain 59 66/1100969
cervix 41 2/48171
connective tissue 6 1/149254
ear 123 2/16212
embryonic tissue 23 5/215722
esophagus 0 0/20208
eye 37 8/211052
heart 33 3/89625
intestine 17 4/234477
kidney 56 12/211769
larynx 41 1/24144
liver 19 4/207739
lung 17 6/336969
lymph 0 0/44269
lymph node 54 5/91607
mammary gland 135 20/153267
mouth 223 15/67053
muscle 9 1/107711
nerve 0 0/15768
ovary 68 7/102050
pancreas 4 1/214811
parathyroid 48 1/20540
pharynx 0 0/41328
pituitary gland 0 0/16584
placenta 42 12/280828
prostate 21 4/189352
salivary gland 0 0/20155
skin 4 1/210574
spleen 0 0/53953
stomach 10 1/96622
testis 39 13/330449
thymus 36 3/81130
thyroid 0 0/81130
tonsil 0 0/16999
trachea 38 2/52412
umbilical cord 0 0/13680
uterus 12 3/232876
vascular 135 7/51779
*The EST profiles show approximate gene expression patterns, as inferred from
EST counts from cDNA library sources, reported by sequence submitters to
Unigene at the NCBI [63]. Libraries known to be normalized, subtracted, or
otherwise biased are not included.
**TPM = transcripts per million.
***EST/total = number of DIA1 ESTs in the total EST pool.
doi:10.1371/journal.pone.0014534.t002
Table 3. EST profiles of DIA1R gene expression in human
tissues.
cDNA library source* TPM** EST/total***
adipose tissue 76 1/13105
adrenal gland 0 0/33195
Ascites 0 0/40013
Bladder 0 0/29757
Blood 0 0/123476
Bone 0 0/71655
bone marrow 0 0/48798
Brain 25 28/1100969
Cervix 0 0/48171
connective tissue 40 6/149254
Ear 0 0/16212
embryonic tissue 0 0/215722
esophagus 0 0/20208
Eye 0 0/211052
Heart 78 7/89625
Intestine 8 2/234477
Kidney 9 2/211769
Larynx 0 0/24144
Liver 4 1/207739
Lung 5 2/336969
Lymph 0 0/44269
lymph node 0 0/91607
mammary gland 32 5/153267
Mouth 29 2/67053
Muscle 27 3/107711
Nerve 0 0/15768
Ovary 0 0/102050
pancreas 4 4/214811
parathyroid 0 0/20540
Pharynx 0 0/41328
pituitary gland 0 0/16584
Placenta 60 17/280828
Prostate 36 7/189352
salivary gland 0 0/20155
Skin 0 0/210574
Spleen 0 0/53953
Stomach 10 1/96622
Testis 0 0/330449
Thymus 0 0/81130
Thyroid 21 1/81130
Tonsil 0 0/16999
Trachea 19 1/52412
umbilical cord 73 1/13680
Uterus 17 4/232876
Vascular 57 3/51779
*The EST profiles show approximate gene expression patterns, as inferred from
EST counts from cDNA library sources, reported by sequence submitters to
Unigene at the NCBI [63]. Libraries known to be normalized, subtracted, or
otherwise biased are not included.
**TPM = transcripts per million.
***EST/total = number of DIA1 ESTs in the total EST pool.
doi:10.1371/journal.pone.0014534.t003
A DIA1-Related Gene
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brain tissue, the highest expression level of DIA1R was in the
cerebellar peduncles (Figure S3), a region of the brain abnormal in
those with ASD [87–89]. However, microarray studies are plagued
by a lack of reproducibility and accuracy [90–93], and we can not
place too much emphasis on differences between gene expression
levels, but must focus on overall expression profiles. While
quantitative reverse-transcriptase polymerase chain reactions
(RT-PCR) can provide more accurate and reproducible results
[94], and can be used in conjunction with commercially available
human tissue panels, analysis of data from this approach relies on
the choice of reference gene for normalization [95]. Changes in
the comparable housekeeping gene can lead to changes in the
significance and expression of the target gene using RT-PCR
approaches to quantifying gene expression [96,97]. We can
therefore only reliably conclude that human DIA1 and DIA1R
are both ubiquitously expressed genes.
Expression of human DIA1 and DIA1R during
development
To examine expression of DIA1 and DIA1R during human
development, microarray data from the Gene Atlas [76] at the
BioGPS [77] database (Figure S2 and S3) and EST profile data
from UniGene [63], were examined (Tables 4 and 5). As EST data
was restricted by the depth at which each developmental stage
could be sampled, absences of expression cannot be assumed to
indicate a lack of expression. Despite the limitations of EST
profiling, the data revealed that both DIA1 and DIA1R are
expressed in fetal tissue, with DIA1 expression also detected in the
blastocyst (Tables 4 and 5). Microarray data confirmed expression
of DIA1 and DIA1R in fetal brain (Figure S2 and S3). Therefore,
human DIA1 and DIA1R are expressed in both adult and fetal
tissues, including adult and fetal brain.
Discussion
The DIA1 gene, recently identified in a genetic study detecting
autism genes by tracing recent shared ancestry, localizes to
chromosome 3 at position 3q24 [61]. Using a bioinformatics
Figure 4. Microarray gene expression data for DIA1 and DIA1R. Graphical presentation of microarray expression data for (A) DIA1 or (B) DIA1R
in normal, healthy human tissues. The intensity values (shown on the root-scale y-axis) are average values, where variation in the range of
measurements is represented by a white box above the coloured minimal-measurement bar. Tissues are grouped according to their origin and the
groups coloured: red = immune system; green = nervous system; yellow = muscle; blue = secretory glands; pink = ‘other’. Tissue abbreviation (on
the x-axis) legend: BMR=bone marrow; SPL=spleen; TMS=thymus; BRN=brain; SPC=spinal cord; HRT=heart; MSL=skeletal muscle; LVR=liver;
PNC=pancreas; PST=prostate; KDN=kidney; LNG=lung. Data were obtained from the GeneNote database of human genes at the Weizmann
Institute [75], and are MAS5.0 normalized data obtained using the Affymetrix HG-U95 set A–E.
doi:10.1371/journal.pone.0014534.g004
Table 4. EST profiles of DIA1 gene expression during human
development.
cDNA library source* TPM** EST/total***
embryoid body 42 3/70760
blastocyst 32 2/62318
fetus 44 25/564004
neonate 0 0/31097
infant 0 0/23620
juvenile 0 0/55555
adult 31 62/1939097
*The EST profiles show approximate gene expression patterns, as inferred from
EST counts from cDNA library sources, reported by sequence submitters to
Unigene at the NCBI [63]. Libraries known to be normalized, subtracted, or
otherwise biased are not included.
**TPM = transcripts per million.
***EST/total = number of DIA1 ESTs in the total EST pool.
doi:10.1371/journal.pone.0014534.t004
A DIA1-Related Gene
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localizes to the human X chromosome at position Xp11.3. As has
been reported for mouse DIA1 [64], we find both human DIA1
and DIA1R are ubiquitously expressed, suggesting each gene has a
generic cellular role. Furthermore, human DIA1R, like DIA1 [62],
encodes a signal peptide for targeting to the secretory pathway.
Our comparison of human DIA1 and DIA1R at the amino acid
level found conservation greatest between the central portions of
the proteins, indicating this region may contribute to a biological
role shared by each protein. The presence of DIA1R in the human
genome may therefore explain why a homozygous deletion of a
ubiquitously-expressed gene such as DIA1 is not lethal [61].
However, human DIA1R, only has 62% similarity overall to
human DIA1, and presumably cannot fully compensate for loss of
DIA1, which would explain why DIA1 deletion is associated with
the neurological deficits of autism [61].
Role of the DIA1R locus in autism and X-linked mental
retardation
Around 10% of genes on the X chromosome cause XLMR if
inactivated [60]. Human DIA1R is an X-linked gene at position
Xp11.3, and is therefore part of the wider Xp11.3-Xp11.23
region. This wider region is implicated in a growing number of
genetic diseases, including several eye disorders, XLMR, X-linked
neuromuscular diseases, and susceptibility loci for schizophrenia
and type 1 diabetes, with the Xp11.3 locus implicated specifically
in XLMR [98,99]. However, in addition to 19 characterized
genes, there are at least four uncharacterized genes in this region
of the X chromosome, including DIA1R, whose contribution to the
disease phenotypes mapped to this region have not been assessed.
We next highlight a number of publications that support the
hypothesis that deletion of the Xp11.3 region encompassing
DIA1R causes ASD-like symptoms and/or XLMR. Essentially, we
have carried out a retrospective genotype-phenotype analysis
based on previously published studies which characterized the
phenotypic traits of patients with deletions encompassing DIA1R.
Genotype-phenotype mapping is a concept first introduced in
1991 [100], and genotype-phenotype correlation is widely used to
examine the contribution of a certain mutation (genotype) to the
resulting clinical traits (phenotype) [101–106]. Deletions encom-
passing a certain chromosomal region have variable phenotypes,
depending on the size and position of the deleted region. However,
features common to patients with deletions overlapping a locus of
interest provide evidence for the specific effect of the loss of that
gene or genes. The findings outlined below suggest DIA1R is
joining an increasing number of genes able to cause both ASD
and/or MR [45–48].
In the first study, examination of a patient with developmental
delay, no expressive speech, mental retardation, and microceph-
aly, revealed a 4.0-Mb heterozygous deletion at Xp11.3–p11.4.
This region included 5 candidate genes, including DIA1R and
CASK, the latter of which was suggested to be causative due to its
known role in synaptic function [107]. We suggest DIA1R deletion
contributes to the phenotype of this patient.
Secondly, a linkage study of a four-generation family, implicated
chromosomal region Xp11.3–11.21 in a novel neurological
syndrome [108]. The syndrome is characterized by mild mental
retardation, poor verbal skills, aggressive and/or agitated
behaviour, and involuntary movements referred to as choreoath-
etosis. These symptoms overlap with those of ASD, and
choreoathetosis is associated with Rett syndrome [109]. Reyniers
and colleagues [108] discussed the possible role of 11 known genes
with roles in neural signalling and neurotransmission, and how
they might contribute to patient symptoms. The region does not
include the CASK locus, but does include DIA1R, which can now
also be considered a candidate gene for this novel syndrome.
A third study, by Zhang and colleagues [110], linked the region
Xp11.3–Xq22.2 of male members of a large, cross-generational
family group to poor verbal skills, mental retardation, and
microcephaly. Zhang and coworkers discussed OPHN1 as a
candidate gene in this region, as it had previously been implicated
in XLMR [110]. Nonetheless, the authors acknowledged that
uncharacterized genes in this region may contribute to patient
symptoms, and this may include DIA1R.
A fourth study further strengthens the argument that deletion of
the Xp11.3 region, including DIA1R, is implicated in ASD-like
symptoms and XLMR. This study identified a 5 Mb deletion at
Xp11.3–11.4 in Turner syndrome (TS) patients [111], a region
that does not involve OPHN1. TS is a relatively common genetic
disorder, caused by X chromosome monosomy or other X
chromosome defects. TS does not typically affect intellectual
function or expressive verbal abilities, although it can be associated
with reduced visual-spatial and executive skills, and demonstrable
impairments in social skills [112–113]. Overall, TS is associated
with a substantially increased risk of ASD [114]. Good and
colleagues [111] found that deletion of Xp11.3–11.4 is associated
with the development of ASD-like symptoms in TS patients,
including poor eye contact, poor recognition of facial expression,
and impaired social skills. Deletion of this region was also
associated with increased amygdala volumes in TS patients, to
levels typically associated with normal males [111]. Of note, many
studies have also reported increased amygdala volumes in patients
with ASD [115–118], but the phenomenon is not universal and
the finding may be age-dependent [119].
Good and co-workers [111] hypothesized that there is a critical
gene in the Xp11.3–11.4 region that is expressed in two copies in
normal (46,XX) females, and that full dosage compensation does
not occur in normal (46,XY) males or in Turner syndrome females
(45,X), resulting in the increased amygdala volume found in
normal males [120] and TS females [111]. They further suggested
that this unknown gene has implications for autism and may
contribute to the increased male susceptibility to ASD [111]. This
gene cannot be CASK,a sCASK undergoes X-inactivation [111]. As
human DIA1R has recently been shown to escape X inactivation
[121], DIA1R is a good candidate within this locus. Together, these
Table 5. EST profiles of DIA1R gene expression during human
development.
cDNA library source* TPM** EST/total***
embryoid body 0 0/70760
blastocyst 0 0/62318
Fetus 33 19/564004
Neonate 0 0/31097
Infant 0 0/23620
Juvenile 0 0/55555
Adult 23 45/1939097
*The EST profiles show approximate gene expression patterns, as inferred from
EST counts from cDNA library sources, reported by sequence submitters to
Unigene at the NCBI [42]. Libraries known to be normalized, subtracted, or
otherwise biased are not included.
**TPM = transcripts per million.
***EST/total = number of DIA1 ESTs in the total EST pool.
doi:10.1371/journal.pone.0014534.t005
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symptoms and/or XLMR.
A more direct link between DIA1R and XLMR comes from two
independent studies, where point mutations in DIA1R were
implicated in XLMR [60,122]. It should be noted that any
ASD-like symptoms were not commented on in either of these
studies, and may not have been evaluated or specifically ruled-out.
In the first study, a mutation affecting the DIA1R signal peptide (a
change of serine at position 24 to proline or ‘S24P’, using single
amino acid abbreviations) was reported in a single XLMR patient,
while the same mutation was absent in controls [122]. Our
analyses reveal that the mutant DIA1R gene product (DIA1R-
S24P) is still expected to have a functional signal peptide, but the
mutation is predicted to change the signal peptide cleavage site
(data not shown). Therefore, the DIA1R-S24P mutant is still
expected to translocate to the secretory pathway, but the mutation
may affect the size of the mature protein, with resulting impact on
structure and function. In the absence of knowledge about ASD-
like symptoms in this patient, the data currently suggest that
mutation of DIA1R can cause XLMR, but complete deletion of
DIA1R causes ASD-like symptoms with or without MR.
In the second study, a systematic large-scale screen for mutations
implicated in XLMR found recurrent mutations in DIA1R [60]. In
67 XLMR patients a 383G.A mutation in DIA1R was found [60],
where the mutation is part of an arginine-coding residue (codon:
AGA), resulting in an arginine to lysine (mutated codon: AAA)
change in the DIA1R gene product. The amino acid mutation
(R128K) falls within the amino-terminal one-third of the DIA1R
protein.Whilewearecurrentlyinvestigating the conservationofthis
amino acid in the wider DIA1 and DIA1R family, the findings of
Tarpey and colleagues [60] suggest an R128K mutation alters
DIA1R function in the human brain. These two studies
demonstrate that independent DIA1R mutations are specifically
associated with human XLMR, while the deletion studies implicate
DIA1R deletion in autism-like syndromes and/or XLMR.
Overall, multiple lines of evidence now support a role for DIA1R
in ASD and/or mental retardation: (i) the genotype-phenotype
correlation data provided above; (ii) the high degree of amino acid
conservation between DIA1 and DIA1R, where DIA1 is implicated
in ASD [61]; (ii) targeting of both gene products to the Golgi
apparatus, due to the conservation of signal peptide sequence in
DIA1andDIA1R;(iii)theubiquitoustissueexpressionofbothgenes,
including in brain tissue; (iv) and data from our accompanying paper
which indicates an origin of DIA1R from a DIA1 gene duplication
early in the vertebrate lineage [123]. Each of these findings indicate
conserved gene function.Therefore,itisnot surprisingthatmutation
of DIA1R, appears to cause a similar phenotype to deletion DIA1.
(How thesegenes mightfunction withintheGolgi apparatustocause
this phenotype will be discussed below.)
Disorders associated with the human 3q24 locus
In addition to the publication originally describing the homozy-
gous deletion of DIA1 in autism [61], wider deletions encompassing
3q24 (the region of human chromosome 3 encoding the DIA1 gene),
have also been reported. While each patient with a deletion
encompassing 3q24 has unique features, presumably related to
differences in deletion breakpoints between patients, several
common features are found: developmental delay, mental retarda-
tion, and growth delay including microcephaly [124–126]. These
three common symptomsoverlap those described ina subsetof PDD
patients: females with Rett syndrome (where MECP2 is mutated),
patients with Angelman syndrome, and male Rett syndrome-like
patients in which the MECP2 gene is not implicated [127,128].
By contrast, a patient with a deletion mapping cytogenetically to
3q25, showed developmental delay, but lacked the delayed growth
and microcephaly of larger deletions in this chromosomal area
[129]. Another patient with a deletion around 3q25 was specifically
described as having autistic traits, severe learning difficulties,
hypogonadism, and dysmorphic features [130]. These latter two
deletions [129,130] have only been characterized cytogenetically,
which is a relatively imprecise method [131], and it would be
beneficial to map the exact deletion boundaries to confirm whether
the deleted regions encompass DIA1.
Therefore, while a single publication links homozygous DIA1
deletion to autism [61], numerous studies report that deletion of
portions of the 3q24 region encompassing DIA1 are associated with
developmental delay, ASD-like traits, and/or mental retardation
[124–126]. Together, these publications provide further support for
a role for DIA1 in autism etiology, as first proposed by Morrow and
colleagues in 2008 [61].
Why does DIA1 or DIA1R mutation cause autism-like
syndromes?
We have demonstrated that human DIA1 and DIA1R both encode
signal peptides for targeting to the secretory pathway. Indeed, the
DIA1 gene product has been localized, using immunofluorescence
microscopy, to the lumen of the Golgi apparatus [62]. Surprisingly,
for genes with roles in neurological diseases, we find both DIA1 and
DIA1R are ubiquitously expressed, which indicates they fulfil basic,
non-specialist cellular roles. However, despite ASDs being diagnosed
on the behavioural manifestations of neurological deficits [132–135],
many co-morbid non-neuronal conditions occur in ASD patients,
suggesting widespread physiological and biochemical abnormalities
in ASD patients [136–139]. Secretory pathway malfunction is a
plausible explanation for the wide-ranging deficits in ASD and, as
both DIA1 and DIA1R are predicted to play ubiquitous roles in some
aspect of the cellular secretion pathway, they may be involved in a
common cellular pathway deficient in those with ASDs.
The secretory pathway plays a key role in all cells, with essential
roles in neuron development and function. Secretion in neurons,
while having many factors in common to that in non-neuronal cells,
has specific challenges. Recently, dendrites have been found to have
satellite Golgi-like cisternal stack s ,k n o w na sG o l g io u t p o s t s ,w h i c h
have no membranous connection with the somatic Golgi [140]. What
triggers Golgi outpost formation is not known, and only proteins
common to the somatic Golgi have been identified in Golgi outposts
[141]. Therefore, despite using the same secretory compartments as
other cells, the dependence of neurons on the secretory pathway for
synaptic transmission, outgrowth and remodelling of dendrites and
axons, combined the vast distances involved, means the impact of
mutation in many secretory pathway genes has a greater impact on
neuronal, rather than non-neuronal, cell function [142]. Indeed,
aberrations in cell secretion are being detected in increasing numbers
of patients with ASD and/or mental retardation [143–149]. While
large numbers of genes have been implicated as causative of ASD, we
next discuss data suggesting that a common theme in ASD etiology
may be alterations in cellular secretory pathway(s).
Recent work has found that four independent gene rearrange-
ments, all previously implicated in ASD, induce the same
morphological and functional aberrations in the large dense core
granules of platelets [149]. It is also well-established that aberrant
serotonin secretion from platelets is common in those with ASD
[150–151], along with aberrant levels of other secreted factors,
including neuropeptides and neurotrophins [137,143,144]. Fur-
thermore, two research groups have found evidence for defective
enzymatic activity in the secretory pathway of those with autism.
The more recent of these two studies, found a functional deficit in
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saliva of patients with ASD [152]. The activity of this ubiquitously
expressed kinase can affect the traffic and/or function of its
substrates [153–157]. The second research group found a deficit in
the activity of tyrosylprotein sulfotransferase (TPST) in platelets of
patients with ASD [158,159]. TPST is a ubiquitious sulfotransfer-
ase, which acts on substrates in the lumen of the Golgi apparatus
[160]. Protein tyrosine sulfation is again known to affect the
function of the target protein [161]. Therefore, an emerging theme
in autism is defects in the delivery or function of secreted, or cell-
surface, molecules. The location of DIA1 and DIA1R suggests
they may also affect such processes.
Further evidence supporting a role of secretory pathway deficits
inASDetiology,arestudiesidentifyinggenesrelated toglycobiology
in autism [48,162]. As the Golgi apparatus is the main site of
glycosylation [163], this finding further implicates deficits in Golgi
apparatus function in ASD etiology. Therefore, a unifying
hypothesis is that genes involved in the pathogenesis of autism are
involved in regulation of secretion, the expression of secreted
proteins, or the optimal function of proteins trafficking via the
secretory pathway. We propose a model where DIA1 and DIA1R
play a role in regulation of cargo secretion or modification of cargo
molecules, which is required for optimal cargo functionality. We
conclude that defects in DIA1 or DIA1R function within the lumen
of the Golgi apparatus of human cells causes autism and/or mental
retardation. However, in the absence of known protein motifs and
domains (data not shown), ongoing studies are required to
determine the exact cellular roles of human DIA1 and DIA1R,
particularly the effects of mutation on brain function.
Materials and Methods
Detection and chromosome mapping of human DIA1R
The human DIA1 amino acid sequence [61,62] was used in a
BLASTsearch,usingthe BLASTP[65]program,andthisidentified
therelated humansequence,DIA1R,onthenon-redundant protein
database at the NCBI [63]. Chromosomal location and chromo-
some ideograms were obtained using MapViewer at NCBI [63].
Alignments, protein analysis, and homologue
identification
Protein sequence alignments were generated with CLUSTALX
version 1.8 [164]. The ExPASy Compute pI/MW tool [165] was
used to calculate theoretical molecular weights. Three trans-
membrane prediction methods were used to analyze protein
sequences: TMpred [166], TMAP [167], and HMMTOP version
2.0 [168]. Signal peptides were evaluated using SignalP version 3.0
[72] or the SigCleave algorithm [73] which is part of the
EMBOSS software suite [74]. Amino acid motifs and domains
were investigated using the following resources: MOTIF at
GenomeNet [169]; PSORT-II [170]; the Conserved Domain
Database at the NCBI, which also contains data from Pfam,
SMART and COG [171]; and the Eukaryotic Linear Motif
resource [172]. Homologs of human DIA1 and DIA1R were
identified using the NCBI HomoloGene resource [63].
Human tissue expression
EST profiles were obtained via the UniGene database at NCBI
[63] and were accessed on 12
th November 2010. Microarray data
was accessed from the GeneNote normal human expression
database at the Weizman Institute [75] and the Gene Atlas
database [76] via the BioGPS gene portal server [7].
Supporting Information
Figure S1 Neural network prediction of signal peptides in
human DIA1 and DIA1R. The amino acid sequence of (A) human
DIA1 or (B) human DIA1R, was evaluated for amino-terminal
signal peptides using the neural network (NN) algorithm of SignalP
v3.0 [72]. The C-score (cleavage score for each amino acid) is
indicated in red, the S-score (signal peptide score) is indicated in
green, and the Y-score (derived from the C-score and S-score, and
can give a better indication of the cleavage site) is indicated in
blue. The significance cut-off value for all probability scores is 0.5,
and is indicated by a pink dotted line. Standard single-letter amino
acid abbreviations and numbering are provided below the graph.
Found at: doi:10.1371/journal.pone.0014534.s001 (0.02 MB PDF)
Figure S2 BioGPS microarray expression data for DIA1.
Graphical presentation of expression data for DIA1 in a variety of
normal, and cancerous human tissues and cells. Expression values
were obtained from an Affymetrix U133A microarray and relate to
fluorescence intensity. Multiple probes wereused for each transcript
on the microarray and these intensity values have been normalized,
background-subtracted, and summarized using the data-processing
algorithm GCRMA (GeneChip Robust Multi-array Average). The
identifier of the Affymetrix probe set used is indicated above the
graph. Data were obtained from the Gene Atlas database of human
genes [76] at the BioGPS gene portal server [77].
Found at: doi:10.1371/journal.pone.0014534.s002 (0.02 MB PDF)
Figure S3 BioGPS microarray expression data for DIA1R.
Graphical presentation of expression data for DIA1R in a variety
ofnormal,andcancerous humantissues and cells.Expression values
were obtained from an Affymetrix U133A microarray and relate to
fluorescence intensity. Multiple probes wereused for each transcript
on the microarray and these intensity values have been normalized,
background-subtracted, and summarized using the GCRMA
(GeneChipRobustMulti-arrayAverage)data-processingalgorithm.
TheidentifieroftheAffymetrixprobesetusedisindicatedabovethe
graph. Data were obtained from the Gene Atlas database of human
genes [76] at the BioGPS gene portal server [77].
Found at: doi:10.1371/journal.pone.0014534.s003 (0.03 MB PDF)
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